Detalles de la búsqueda
1.
Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the vastus lateralis (lateral thigh) muscles of healthy adult participants.
Antimicrob Agents Chemother;
68(1): e0078123, 2024 Jan 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38038460
2.
Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP.
Antimicrob Agents Chemother;
: e0147523, 2024 May 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38709006
3.
Asian participants' experience in phase 3/3b studies of long-acting cabotegravir and rilpivirine: Efficacy, safety, pharmacokinetic, and virological outcomes through week 96.
HIV Med;
25(3): 381-390, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38147871
4.
Efficacy, safety, and pharmacokinetics by BMI category in Phase 3/3b cabotegravir + rilpivirine long-acting trials.
J Infect Dis;
2023 Dec 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38134313
5.
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study.
Clin Infect Dis;
76(9): 1646-1654, 2023 05 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36660819
6.
Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure.
Clin Infect Dis;
77(10): 1423-1431, 2023 11 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-37340869
7.
Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083.
Antimicrob Agents Chemother;
67(4): e0005323, 2023 04 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-36995219
8.
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
N Engl J Med;
382(12): 1124-1135, 2020 03 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-32130806
9.
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.
N Engl J Med;
382(12): 1112-1123, 2020 03 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-32130809
10.
Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long-acting cabotegravir and rilpivirine in clinical trials.
HIV Med;
24(5): 568-579, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36411596
11.
Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084.
J Infect Dis;
225(10): 1741-1749, 2022 05 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-35301540
12.
Safety, Tolerability, Pharmacokinetics, and Acceptability of Oral and Long-Acting Cabotegravir in HIV-Negative Chinese Men.
Antimicrob Agents Chemother;
66(3): e0205721, 2022 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35129374
13.
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Lancet;
396(10267): 1994-2005, 2021 12 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-33308425
14.
A population pharmacokinetic model based on HPTN 077 of long-acting injectable cabotegravir for HIV PrEP.
Br J Clin Pharmacol;
88(10): 4623-4632, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35949044
15.
Multiparametric magnetic resonance imaging to characterize cabotegravir long-acting formulation depot kinetics in healthy adult volunteers.
Br J Clin Pharmacol;
88(4): 1655-1666, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34240449
16.
Multicompartmental pharmacokinetic evaluation of long-acting cabotegravir in healthy adults for HIV preexposure prophylaxis.
Br J Clin Pharmacol;
88(4): 1667-1678, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34240467
17.
Population pharmacokinetics of cabotegravir following administration of oral tablet and long-acting intramuscular injection in adult HIV-1-infected and uninfected subjects.
Br J Clin Pharmacol;
88(10): 4607-4622, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35695476
18.
Evaluation of the effect of UGT1A1 polymorphisms on the pharmacokinetics of oral and long-acting injectable cabotegravir.
J Antimicrob Chemother;
75(8): 2240-2248, 2020 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32361755
19.
Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults.
J Antimicrob Chemother;
75(3): 648-655, 2020 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31873746
20.
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
Lancet;
390(10101): 1499-1510, 2017 Sep 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-28750935